Business Context and Reporting Period
Company: Mesoblast Limited (ASX: MSB; Nasdaq: MESO)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Nine months ended March 31, 2023 (unaudited)
Business Overview: Mesoblast is a clinical-stage biotechnology company developing allogeneic cellular medicines based on mesenchymal lineage adult stem cells. Key product candidates include remestemcel-L (for steroid-refractory acute Graft versus Host Disease) and rexlemestrocel-L (for chronic heart failure and chronic low back pain).
Key Financial Metrics
| Metric (in thousands USD) | Nine Months Ended March 31, 2023 |
Nine Months Ended March 31, 2022 |
|---|---|---|
| Revenue | $5,362 | $7,987 |
| Net Loss | $(59,970) | $(69,892) |
| Loss Per Share (Basic & Diluted) | $(0.0829) | $(0.1078) |
| Operating Cash Flow | $(46,991) | $(51,888) |
| Cash and Cash Equivalents (End of Period) | $48,799 | $76,760 |
| Total Borrowings | $106,357 | $96,634 |
| Net Debt | $(70,259) | $(48,643) |
Note: Revenue consists primarily of royalty income from licensed products (TEMCELL in Japan and Alofisel in Europe). No milestone revenue was recognized in the current period.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 33% ($2.6 million) compared to the prior year. This was driven by a $1.5 million decrease in royalty income from TEMCELL sales in Japan (partially due to foreign exchange impacts) and the absence of a $1.2 million regulatory milestone payment from Takeda recognized in the prior period.
- Reduced Net Loss: Net loss improved by 14% ($9.9 million) to $60.0 million. This improvement was primarily due to a $6.7 million increase in fair value remeasurement gains on contingent consideration and a $7.3 million decrease in Research & Development expenses.
- Expense Reductions: R&D expenses decreased by 26% ($7.3 million) due to reduced third-party costs for Phase 3 clinical trials as they transitioned to monitoring phases. Management and administration expenses decreased by 7% ($1.6 million), largely due to lower legal and professional fees.
- Debt and Financing: Borrowings increased by $9.7 million to $106.4 million, reflecting accrued interest and remeasurement adjustments on the Oaktree and NovaQuest facilities. The company recognized a $1.2 million loss on the remeasurement of warrant liabilities.
- Tax Incentives: The company recognized $3.1 million in research and development tax incentive income in the current period, compared to nil in the prior period.
Guidance, Outlook, and Risks
- Regulatory Milestones: The FDA accepted the resubmission of the Biologics License Application (BLA) for remestemcel-L in pediatric SR-aGVHD on March 7, 2023, with a PDUFA goal date of August 2, 2023. A Pre-License Inspection (PLI) of manufacturing operations was scheduled.
- Clinical Updates: Long-term survival results for remestemcel-L showed durable survival through 4 years. The DREAM-HF Phase 3 trial results for rexlemestrocel-L in chronic heart failure were published, showing improved heart function and reduced cardiovascular events.
- Liquidity and Going Concern: As of March 31, 2023, cash reserves were $48.8 million. The filing explicitly states there is material uncertainty regarding the company's ability to continue as a going concern due to projected expenditures over the next 12 months exceeding current cash reserves without additional financing.
- Recent Capital Raise: Subsequent to the reporting period (April 25, 2023), the company completed a global private placement raising approximately $40.0 million net of transaction costs.
- Debt Covenants: The company must maintain a minimum unrestricted cash balance of $35.0 million in the U.S. to comply with Oaktree loan covenants. Failure to meet covenants could result in acceleration of debt.
- Legal Proceedings: The company is defending against consolidated shareholder class actions in Australia and a settled class action in the U.S. related to FDA communications and stock price declines in 2020.
Investor Verification Checklist
- Going Concern Status: Verify the impact of the $40 million post-period capital raise on the "material uncertainty" regarding the company's ability to continue operations for the next 12 months.
- BLA Approval Probability: Assess the likelihood of FDA approval for remestemcel-L by the August 2, 2023 PDUFA date, given the recent Pre-License Inspection.
- Debt Structure: Review the terms of the Oaktree and NovaQuest facilities, specifically the interest rates (9.75% and 15% respectively), payment caps, and the risk of debt acceleration if covenants are breached.
- Revenue Sustainability: Evaluate the dependency on royalty income from JCR (Japan) and Takeda (Europe) and the impact of foreign exchange rates on future revenue recognition.
- Legal Exposure: Monitor the status of the consolidated Australian class action lawsuits and potential settlement costs.